Solid Biosciences to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB), a precision genetic medicines company, announces participation in two major healthcare conferences. At Citi's 2024 Global Healthcare Conference in Miami, President and CEO Bo Cumbo will join a panel on Neuromuscular Disorders on December 4, 2024, at 1:00 p.m. ET. The following day at the Piper Sandler 36th Annual Healthcare Conference in New York, Cumbo and Chief Medical Officer Gabriel Brooks will participate in a fireside chat at 9:30 a.m. ET. Both events will be webcast live and available for replay on the company's website for 30 days.

CHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:

• Citi’s 2024 Global Healthcare Conference – Miami, FL
  Bo Cumbo, President and CEO, will participate in a panel discussion titled “Neuromuscular Disorders” on Wednesday, December 4, 2024, at 1:00 p.m. ET.

• Piper Sandler 36^th Annual Healthcare Conference – New York, NY
  Mr. Cumbo and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat on Thursday, December 5, 2024, at 9:30 a.m. ET.

Live webcasts of the Citi panel discussion and Piper Sandler fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.

Institutional investors interested in meeting with management during the conference may reach out to their Citi or Piper Sandler representatives.

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

FAQ

When is Solid Biosciences (SLDB) presenting at Citi's 2024 Global Healthcare Conference?

Solid Biosciences will participate in a panel discussion on Neuromuscular Disorders at Citi's 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 1:00 p.m. ET in Miami, FL.

What events will Solid Biosciences (SLDB) participate in during December 2024?

Solid Biosciences will participate in Citi's 2024 Global Healthcare Conference on December 4 and the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024.

How long will the webcasts be available for Solid Biosciences' (SLDB) December 2024 conference presentations?

The webcasts of both conference presentations will be archived and available for replay for 30 days on the Events page of the company's website.

Who will represent Solid Biosciences (SLDB) at the Piper Sandler Healthcare Conference?

Bo Cumbo, President and CEO, and Gabriel Brooks, Chief Medical Officer, will represent Solid Biosciences at the Piper Sandler Healthcare Conference fireside chat.